These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

654 related items for PubMed ID: 9130710

  • 1. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.
    Graus-Porta D, Beerli RR, Daly JM, Hynes NE.
    EMBO J; 1997 Apr 01; 16(7):1647-55. PubMed ID: 9130710
    [Abstract] [Full Text] [Related]

  • 2. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
    Pinkas-Kramarski R, Lenferink AE, Bacus SS, Lyass L, van de Poll ML, Klapper LN, Tzahar E, Sela M, van Zoelen EJ, Yarden Y.
    Oncogene; 1998 Mar 12; 16(10):1249-58. PubMed ID: 9546426
    [Abstract] [Full Text] [Related]

  • 3. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
    Alimandi M, Wang LM, Bottaro D, Lee CC, Kuo A, Frankel M, Fedi P, Tang C, Lippman M, Pierce JH.
    EMBO J; 1997 Sep 15; 16(18):5608-17. PubMed ID: 9312020
    [Abstract] [Full Text] [Related]

  • 4. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
    Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y.
    EMBO J; 1996 Jan 15; 15(2):254-64. PubMed ID: 8617201
    [Abstract] [Full Text] [Related]

  • 5. Bivalence of EGF-like ligands drives the ErbB signaling network.
    Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin BJ, Sela M, Andrews GC, Yarden Y.
    EMBO J; 1997 Aug 15; 16(16):4938-50. PubMed ID: 9305636
    [Abstract] [Full Text] [Related]

  • 6. ErbB kinases and NDF signaling in human prostate cancer cells.
    Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ.
    Oncogene; 1997 Nov 27; 15(22):2705-16. PubMed ID: 9400997
    [Abstract] [Full Text] [Related]

  • 7. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells.
    Daly JM, Jannot CB, Beerli RR, Graus-Porta D, Maurer FG, Hynes NE.
    Cancer Res; 1997 Sep 01; 57(17):3804-11. PubMed ID: 9288791
    [Abstract] [Full Text] [Related]

  • 8. Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta.
    Riese DJ, Bermingham Y, van Raaij TM, Buckley S, Plowman GD, Stern DF.
    Oncogene; 1996 Jan 18; 12(2):345-53. PubMed ID: 8570211
    [Abstract] [Full Text] [Related]

  • 9. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
    Daly JM, Olayioye MA, Wong AM, Neve R, Lane HA, Maurer FG, Hynes NE.
    Oncogene; 1999 Jun 10; 18(23):3440-51. PubMed ID: 10376522
    [Abstract] [Full Text] [Related]

  • 12. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors.
    Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M.
    Oncogene; 1997 May 01; 14(17):2099-109. PubMed ID: 9160890
    [Abstract] [Full Text] [Related]

  • 13. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y, Li X, Jiang J, Frank SJ.
    Oncogene; 2006 Dec 07; 25(58):7565-76. PubMed ID: 16785991
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor.
    Azios NG, Romero FJ, Denton MC, Doherty JK, Clinton GM.
    Oncogene; 2001 Aug 23; 20(37):5199-209. PubMed ID: 11526509
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Growth factor-independent proliferation of rat mammary carcinoma cells by autocrine secretion of neu-differentiation factor/heregulin and transforming growth factor-alpha.
    Ethier SP, Langton BC, Dilts CA.
    Mol Carcinog; 1996 Feb 23; 15(2):134-43. PubMed ID: 8599580
    [Abstract] [Full Text] [Related]

  • 18. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors.
    Sanderson MP, Dempsey PJ, Dunbar AJ.
    Growth Factors; 2006 Jun 23; 24(2):121-36. PubMed ID: 16801132
    [Abstract] [Full Text] [Related]

  • 19. Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities.
    Beerli RR, Hynes NE.
    J Biol Chem; 1996 Mar 15; 271(11):6071-6. PubMed ID: 8626392
    [Abstract] [Full Text] [Related]

  • 20. Heregulin-dependent translocation and hyperphosphorylation of ErbB-2.
    Zhou W, Carpenter G.
    Oncogene; 2001 Jun 28; 20(29):3918-20. PubMed ID: 11439355
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.